Clinical Trial Update: Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating the efficacy and safety of vortioxetine for major depressive disorder; results were posted in 2013 following completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Vortioxetine (vortioxetine)

Snippet

Sponsor: Takeda | Conditions: Depressive Disorder, Major | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2013-12-18